Bd introduces high-throughput single-cell multiomics platform to expand scope of scientific discovery

New bd rhapsody™ ht xpress system and other innovations to be unveiled at agbt, enhancing an end-to-end single-cell multiomics offering franklin lakes, n.j. , feb. 3, 2023 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced a new instrument for single-cell multiomics analysis that will enable scientists to run high-throughput studies without sacrificing sample integrity – potentially accelerating time to discovery across a wide range of disciplines including immunology, genetic disease research, and cancer and chronic disease research.
BDX Ratings Summary
BDX Quant Ranking